Patient-reported outcomes
fatigue
CHRONIC MYELOID LEUKEMIA
The completion rate for MD Anderson Symptom Inventory–chronic myeloid leukemia (MDASI-CML) was 96% with asciminib and 92% with bosutinib at baseline and 79.5% and 72.2%, respectively, at week 96. The mean total symptom score at baseline across both treatment arms was 2.0 (on a ten-point scale), with fatigue being the most severe (4.0). Most symptoms either remained stable or decreased in severity from baseline with asciminib (for ≤96 weeks), particularly fatigue, upset feeling, and mood (Supplementary Fig. 